Kornimate/medical-research-clean huggingface dataset:
sclerotherapy and bone marrow injection in aneurysmal bone cyst

Conditions: Orthopedic Disorder

Summary: aneurysmal bone cysts (abcs) are benign, locally destructive growing bone tumors, which were first described in 1942 by jaffé and lichtenstein (1). they are most often diagnosed in childhood and early adulthood. the literature reports that abcs comprise 1-6% of all primary benign bone tumors (2). most cases of abcs (75-90%) are reported for patients younger than 20 years, with a slightly higher incidence for females (3). most common localizations are the pelvis, the metaphysis of long bones and the spine, but abcs can also affect any other localization(2). abcs that are associated with a preexisting osseous lesion are defined as secondary abcs. they represent approximately 30% of all abcs (2). secondary abcs can occur, e.g., in cases of a giant cell tumor, chondroblastoma or telangiectatic osteosarcoma

the clinical symptoms of an abc are usually accidently discovered or may consist of pain and swelling in the affected region and pathological fractures ( complete and incomplete ) can be observed occasionally. in conventional radiography a relatively well-defined osteolytic, expansile lesion with possible blowout of the periosteum and a soap-bubble appearance can be found (4). mri scanning shows cystic formations with typical fluid-fluid levels due to blood sedimentation (7). because of the possible rapid growth with local destruction, the literature describes cases of abcs that mimic malignant bone tumors

Eligibility criteria:
inclusion criteria: * all patients above age of 1 year. * the affected area was all bones except skull, ribs, and other non-orthopedic specialties. * primary or recurrent abc * incomplete fractured affected bones as greenstick fracture. * healed pathological fracture without any surgical intervention exclusion criteria: * abc. in skull, ribs, and other non-orthopedic specialties. * age less than 1 year * suspected malignancy or other bone cysts * complete fractured bones and healed pathological fracture with surgical intervention.
enhancing quality of life in patients (equip) intervention for patients with advanced lung cancer

Conditions: Advanced Lung Cancer

Summary: i. project background patients with advanced lung cancer have a high symptom burden and low quality of life. early palliative care improves patient outcomes in newly diagnosed advanced lung cancer patients, but previously tested models are not feasible for widespread adoption. hence, the aim of this study is to pilot a more sustainable nurse-led intervention - enhancing quality of life in patients (equip). ii. hypothesis / aim the aims of this study are three-fold. firstly, the investigators aim to determine the feasibility and acceptability of the equip intervention itself. secondly, the investigators aim to obtain a tentative estimate of efficacy of the equip intervention. thirdly, the investigators aim to determine the data completion rate of patient reported outcome measures in the context of the equip trial. iii. methods patients with newly diagnosed stage 3 or stage 4 lung cancer will be recruited and randomized to the equip intervention or usual care (control) group. patients randomized to the equip intervention group will receive four face-to-face sessions with a palliative care nurse. the content of these educational sessions will equip patients with the knowledge and skills to manage the three commonest symptoms of fatigue, breathlessness and anxiety. all participants will complete the functional assessment of cancer therapy - lung (fact-l), the hospital anxiety and depression scale (hads) and the stigma subscale at four time points: baseline, 4, 8 and 12 weeks after recruitment. measures of healthcare use will also be recorded. additionally, participants in the intervention group will complete a feedback survey after each intervention session. a total sample of 60 patients (30 in each arm) will be recruited. clinical significance if successful, this study will lead to a larger scale phase iii trial which tests various components of the equip intervention, in order to develop a sustainable and effective model for the provision of palliative care to advanced lung cancer patients.


Eligibility criteria:
inclusion criteria * has stage 3 or 4 lung cancer * ecog 0,1 or 2 * able and willing to participate in the equip programme exclusion criteria - unable to communicate in english or mandarin
telecare north diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: this feasibility study will evaluate the feasibility of two telemonitoring designs for non-insulin treated t2d patients with an eye to identify the most suitable telemonitoring intervention for a future large-scale randomized trial.

background: maintaining optimal glycaemic control in type 2 diabetes (t2d) is difficult. telemedicine has potential to support poorly controlled people with t2d in the achievement of glycaemic control if the telemedicine solution includes a telemonitoring component. however, only few telemonitoring solutions for non-insulin treated t2d exist. therefore, the aim of this feasibility study is to evaluate the feasibility of two telemonitoring intervention designs for non-insulin treated t2d patients with an eye to identify the most suitable telemonitoring intervention for a future large-scale randomized trial. method: the trial will be conducted as a three-month randomized feasibility study in four municipalities in north denmark with 15 participants from each municipality. two different telemonitoring intervention designs will be tested. one intervention will include self-monitoring of blood glucose (smbg) together with monitoring of sleep and mental health. the second intervention will include an identical setup but with the addition of blood pressure and activity monitoring. two municipalities will be allocated to one intervention design, whereas the other two municipalities will be allocated to the second intervention design. qualitative interviews with participants and clinicians will be conducted to gain insight into their experiences with and acceptance of the intervention designs and trial procedures (e.g., blood sampling and questionnaires). in addition, differences in direct intervention costs between the two alternative interventions will be evaluated.

Eligibility criteria:
inclusion criteria: * women and men ≥ 18 years * poorly controlled t2d, i.e. hba1c \> 58 mmol/mol * diagnosis of t2d for at least 12 months * general practitioner responsible for diabetes treatment * residence in hjørring, morsø, jammerbugt, or rebild municipality * ability and willingness to use a smartphone/tablet along with the other devices to be used in the trial * signed informed consent * ability to understand and read danish exclusion criteria: * pregnancy or breastfeeding * insulin treatment * prednisolone treatment * severe diabetes complications such as severe neuropathy or nephropathy (dialysis treatment) * participation in diabetes rehabilitation courses * participation in other intervention trials * terms that, in the opinion of the sub-investigator or investigator, render the participant unfit to conduct the trial, including lack of understanding of the trial or lack of physical or cognitive ability to participate

Keywords: blood glucose diabetes mellitus type 2 telemedicine telehealth telemonitoring feasibility
the purpose of this study is to evaluate safety and performance of the v-strut© transpedicular vertebral system

Conditions: Vertebral Compression Fracture

Summary: the purpose of this pilot study is to evaluate the safety and performance of the v-strut© transpedicular vertebral system for the treatment of vertebral compression fractures of the thoracic or lumbar spine.


Eligibility criteria:
inclusion criteria : * adult male and female patients * treatment of vertebral compression fracture (type a.1, some a.2 and rarely a.3 magerl classification) * due to osteoporosis or tumorous lesions, * located in the thoracic and/or lumbar spine from t9 to l5. * one unique vertebral fracture to be treated with the device * pain \> 4 * asa \> 5 * for osteoporotic patient, fail in conservative treatment (8 days of antalgic medication level iii) and recent fracture (less than 6 weeks). exclusion criteria: * unstable fractures or neoplasms with posterior involvement * nonmobile fractures * damages of the pedicles or posterior wall * less than one third of the original vertebral body height remaining * spinal canal stenosis (\>20%) * neurologic signs or symptoms related to the compression fracture or impeding pathological fracture * patient clearly improving on conservative treatment * pregnancy, breastfeeding * any contra-indication / allergy to implant material or cement * any previous surgical treatment (material or cement) in the targeted vertebra * systemic infection or infection located in the spine * any medical condition including but not limited to anaemia, coagulation disorders, fibromyalgia, algoneurodystrophy, paget's disease, uncontrolled diabetes that would preclude the patient from having surgery or would impede the benefit of surgery * patient under the age of majority
mrd assay evaluates recurrence and response via a tumor informed assessment

Conditions: Cancer; Solid Tumor; Non Small Cell Lung Cancer; Colorectal Cancer; Bladder Cancer

Summary: this study recruits patient with solid tumor types for sample collection and monitoring. participants will provide blood and archival tissue samples in order to create a personalized cancer monitoring (pcm) assay. this assay will be used to detect circulating tumor dna (ctdna) levels in the blood over time and hopefully contribute to improvements in residual disease detection methods for future patients. results from this assay will be provided to participants and providers but providers are not asked to change patient care based on this information.

this study involves collection of tumor tissue (from a standard biopsy and/or surgery) as well as blood samples over time in order to allow the creation of a personalized cancer monitoring (pcm) assay. additional blood samples are taken throughout the patient's treatment and follow-up period. each participant will submit one blood sample when they begin participation in the research study. participants will be asked to submit follow up samples several times per year (annually, at minimum), with the exact frequency varying by stage and type of cancer. in general, participants will not be asked to come into the clinic more frequently than their already needed clinic visits. if the cancer-specific mutations identified by the pcm are detected in the blood samples provided as part of the study, this may would suggests that residual cancer may be present. this is an observational study comparing mrd results to standard of care methods and collecting provider and patient perspectives, using surveys. physicians will be informed of all pcm results in the form of a clinical report. physicians are not asked to base treatment decisions on these results.

Eligibility criteria:
inclusion criteria 1. stated ability to give informed consent by participant. 2. stated health status of participant as healthy enough to provide biological material. 3. individuals diagnosed with solid cancer of any type, including but not limited to colorectal, non-small cell lung, breast, ovarian and bladder cancers, regardless of the length of time since diagnosis and regardless of previous therapies. 4. participant is of any biological sex and \>18 years of age 5. participant has not undergone a blood transfusion within the previous three weeks exclusion criteria 1. participants who are deemed medically unstable 2. participants who are deemed to be "difficult to draw" blood from. 3. participants who are \<18 years of age 4. participants diagnosed with cns cancers, sarcomas or hematologic malignancies such as leukemia or lymphoma . 5. participants with more than one primary cancer 6. participants with ffpe slides older than 10 years 7. participants who are pregnant 8. any other reason that, in the investigator's judgment, that would preclude the participant from being able to participate in the study 9. participants for which a pathology report is not available

Keywords: minimal residual disease mrd ctdna circulating tumor dna
safety surveillance of pneumococcal 13-valent conjugate vaccine among filipinos

Conditions: Pneumococcal Disease

Summary: prevenar 13 is safe for administration to filipinos.

filipino patients prescribed and administered with the vaccine will be monitored for safety patients prescribed with the vaccine who provides consent for inclusion to the study will be observed.

Eligibility criteria:
inclusion criteria: patients prescribed with the vaccine exclusion criteria: patients with hypersensitivity to the vaccine
purpose project: reclaiming life purpose after breast cancer (feasibility study)

Conditions: Breast Cancer

Summary: the purpose project intervention is an 8-session progressive structure that was developed based on theoretical and scientific evidence from psychology and occupational therapy. the goal of the intervention is to provide participants with information, tools, and support that help them move towards reclaiming a sense of self-grounded purpose in daily life. the study will use a convenience sample of women with breast cancer to evaluate the feasibility of the purpose project intervention in terms of demand/acceptability, implementation, and limited-efficacy testing. findings will be used to inform a later study to evaluate the efficacy of the purpose project intervention.


Eligibility criteria:
inclusion criteria: 1. between 25 and 74 years of age 2. completed chemotherapy and/or radiation treatment for stage 1, 2, or 3 breast cancer up to 5 years prior to study enrollment 3. english speaking 4. graduated from high school 5. able to see, hear, speak (with or without assistive devices) 6. able to provide own transportation to sessions 7. willing and able to commit to attend all 8 intervention sessions, 2 testing sessions, and the one-to-one interview that occurs after completing the 8 intervention sessions. exclusion criteria: 1. stage 4 breast cancer or any other stage 4 cancer 2. actively receiving chemotherapy or radiation treatments for cancer. (however, patients may be on herceptin and/or endocrine treatment and participate in the study.) 3. history of neurologic disorder (such as stroke or brain injury) with residual impairments that likely interfere with learning 4. any medical condition (physical or mental health) that interferes with the performance of everyday activities and roles.
metabolism, circadian rhythms and ovarian function

Conditions: Chemotherapy-Induced Amenorrhea

Summary: chemotherapy for cancer, due to its gonadotoxicity, can lead to impaired female fertility, resulting in the occurrence of transient or prolonged chemo-induced amenorrhea (cia). according to recent data from the national cancer institute, 11.9% of women under the age of 40 diagnosed with cancer have been offered a fertility evaluation within five years of diagnosis. predicting the risk and especially the duration of the cia remains difficult. known factors predicting a rapid return of menstruation are a young age at diagnosis, a low gonadotoxic treatment (absence of alkylating agents) and a high pre-chemotherapy blood level of amh reflecting a large pool of growing follicles. a body mass index (bmi) ≥ 25 kg / m² could also be a positive predictor, but this remains debated. the objective of this project is to assess the impact of metabolism and energy reserves, physical activity and the chronotype on the recovery of ovarian function in patients with breast cancer who have developed cia


Eligibility criteria:
inclusion criteria: * women with a chemotherapy-induced (cia) amenorrhea who asked for post-cancer fertility follow-up at the university hospital of lille, france. * women between 25 to 35 years age at inclusion * chemotherapy protocol: fec 100 (3 cycles) + docetaxel (3 cycles exclusion criteria: * women without cia * women who refuse to participate in the study * women older than 35 years at inclusion * women who received another chemotherapy protocol

Keywords: ovarian recovery metabolism muscular mass adipose tissue chronotype
identification of novel molecular markers for vasospasm

Conditions: Cerebral Vasospasm; Subarachnoid Hemorrhage

Summary: the purpose of the study is to identify novel genetic and protein markers for the process of cerebral vasospasm following aneurysmal subarachnoid hemorrhage.

cerebral vasospasm is a recognized and poorly understood complication for many patients who have aneurysmal subarachnoid hemorrhage. constriction of the cerebral arterial vasculature occurs as free subarachnoid blood under high pressure comes into contact with the surfaces of vessels, particularly in the basal cisterns. however, the exact pathophysiology of vasospasm is unknown. morbidity and mortality rates for vasospasm are high despite improvements in management. excluding the initial hemorrhage, cerebral vasospasm is recognized as the main cause of substantial disability and death. cerebral vasospasm kills 7% of patients, and causes severe deficit in another 7%. cerebral vasospasm almost never occurs before day 3, has maximal incidence at days 6-8, and rarely occurs after day 17. the disorder is clinically characterized by confusion or decreased consciousness with focal neurological deficit. experimental evidence suggests that red blood cell hemolysis and subsequent release of oxygen, hemoglobin, reactive oxygen species, and other as yet undescribed mediators are necessary for the development of vasospasm. the goal of this study is to use modern tools of genomics to identify novel molecular markers for the process of vasospasm by studying the release of micro ribonucleic acids (rna) that are secreted into the cerebrospinal fluid following the initiation of vasospastic cascades. micro rna's have recently been identified as important regulators of many cellular processes including cell cycle progression, proliferation, tumor suppressors, oncogenes, and regulators of metabolic pathways. the researchers propose to study the levels of annotated micro rna's in the cerebrospinal fluid (csf) of patients who present with subarachnoid hemorrhage from presentation through the hospital stay. the researchers will correlate the level of these micro rna's with patient clinical presentation, including transcranial doppler measurements, glasgow coma scale score, vital signs, and angiographic studies. it is well established that the process of vasospasm occurs over the course of many days. long before vasospasm becomes clinically evident, cellular processes causing spasm are in action and the researchers hope to identify micro rna mediators of these processes using high throughput screening methods.

Eligibility criteria:
inclusion criteria: * adult patients with aneurysmal subarachnoid hemorrhage within 24-hours of bleed. * receive either open vascular clipping or endovascular coiling. exclusion criteria: * patients under 18 years of age. * patients arriving at the hospital \>24-hours post-hemorrhage. * patients who are not candidates for further care.
effect of actonel on periodontal health of postmenopausal women

Conditions: Periodontal Disease

Summary: hypothesis: women who use actonel (risedronate) for osteopenia will show beneficial periodontal effects.

women who use actonel for osteopenia will show beneficial attachment loss, alveolar bone height and morphology as compared to those who do not when oral hygiene is corrected for.

Eligibility criteria:
inclusion criteria: * osteopenia * postmenopausal exclusion criteria: * male * diabetes

Keywords: osteopenia periodontitis
efficacy and safety of imatinib in scleroderma

Conditions: Scleroderma, Localized; Scleroderma, Systemic

Summary: in vitro studies have shown that imatinib 1mm inhibits strongly the growth of cutaneous fibroblasts. the hypothesis is that imatinib inhibits pdgfr which is known to be a potential target for the molecule, as recently also proposed after the discovery of autoantibodies activating the pdgf receptors. recent data indicate that tgfb is also a potential target of imatinib. cutaneous scleroderma is characterized by progressive cutaneous fibrosis caused by hyperactive dermal fibroblasts. since no established treatment for skin sclerosis in scleroderma is currently available. this study will test the safety and efficacy of imatinib in the treatment of patients with scleroderma and severe cutaneous involvement.

this study will test the efficacy and tolerance of patients with a high score of induration (modified rodnan score \> 20/54) comparison : 34 patients with severe forms of cutaneous involvement will be evaluated in a double blind rct comparing imatinib 400mg/j and placebo in a 6 month period. efficacy will be assessed using a cutaneous induration scale and skin biopsy, and quality of life questionnaires.

Eligibility criteria:
inclusion criteria: * more than 18 years old * documented diagnostic of scleroderma (systemic or cutaneous) * severe cutaneous sclerodermia or systemic sclerodermia with m-rodnan score \> 20/51 * ejection fraction of more than 45 per cent at cardiac ultrasound pre-inclusion study * woman with efficient contraceptive method during trail treatment and during 3 month after the end of trial treatment * all female patients with reproductive potential must have a negative pregnancy test (serum or urine) within the 7 days prior to enrolment * affiliated or profit patient of a social security system * signed informed consent exclusion criteria: * new systemic treatment, potentially interfering with disease progression, beginning 3 months prior the start trial treatment * patient with isolated cutaneous scleroderma treated with a drug potentially interfering with the course of the disease 4 weeks before starting the trial (systemic corticosteroids, methotrexate, cyclophosphamide, bosentan) * scleroderma " en coup de sabre " * severe organ failure or anomaly of blood chemistry/hematology (bilirubin, sgot, sgpt, creatinine \> 1,5 ´ upper normal limit, polymorphonuclear granulocytes less than 1\*10\*9/l or platelets less than 50\*10\*9/l), * ongoing cancer * ejection fraction ≤ 45 per cent at cardiac ultrasound pre inclusion study * myocardial infarction of less than 6 mois at pre inclusion visit * non controlled chronic illness (diabetes, chronic kidney failure, chronic hepatitis, hiv infection), * major surgery less than two weeks before inclusion * pregnancy or lactation * absence of validated contraception in childbearing women. * contraindication to imatinib mesylate treatment as specified in product specifications * non observance anticipated and absence of informed consent

Keywords: scleroderma imatinib pdgfr rodnan